Excellent Response to Oral Etoposide in HER2-Positive Metastatic Breast Cancer (MBC)
Tóm tắt
Từ khóa
Tài liệu tham khảo
Slamon DJ, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92.
Swain SM, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372:724–34.
Johnston SRD, et al. Phase III, randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor-positive metastatic breast cancer: alternative. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36:741–8.
Verma S, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783–91.
Freedman RA, et al. TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37:1081–9.
Bang YJ, et al. First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. Ann Oncol Off J Eur Soc Med Oncol. 2017;28:855–61.
Panigrahy D, et al. Inhibition of tumor angiogenesis by oral etoposide. Exp Ther Med. 2010;1:739–46.
Cabel L, et al. Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens. Breast Cancer Res Treat. 2019;173:397–406.